Anal Cancer Market Research Report Information by Cancer Type (Carcinoma in Situ, Squamous Cell Carcinoma, Adenocarcinoma, Basal Cell Carcinoma, Melanoma and others), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and Immunotherapy), End User (Hospitals & Clinics, Research & Academic Institutes and others) - Forecast till 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL ANAL CANCER MARKET, BY CANCER TYPE

6.1. Overview

6.2. Carcinoma in Situ

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Squamous Cell Carcinoma

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Adenocarcinoma

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Basal Cell Carcinoma

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Melanoma

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL ANAL CANCER MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Chemotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Surgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Radiation Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Immunotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL ANAL CANCER MARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL ANAL CANCER MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Anal Cancer Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Anal Cancer Market

10.7. Key Developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. Amgen Inc.

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Bristol-Myers Squibb Company

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Celgene Corporation

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Eli Lilly and Company

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. F. Hoffmann-La Roche Ltd

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Merck & Co., Inc.

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Pfizer Inc.

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. GlaxoSmithKline plc

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Sanofi

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Johnson & Johnson Services, Inc.

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Hospira, Inc.

11.12.1. Company Overview

11.12.2. Product Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANAL CANCER MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL ANAL CANCER MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL ANAL CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 12 US: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 15 CANADA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: ANAL CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: ANAL CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: ANAL CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE OF THE GLOBAL ANAL CANCER MARKET

FIGURE 3 MARKET DYNAMICS OF THE GLOBAL ANAL CANCER MARKET

FIGURE 4 GLOBAL ANAL CANCER MARKET SHARE, BY CANCER TYPE, 2020 (%)

FIGURE 5 GLOBAL ANAL CANCER MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 6 GLOBAL ANAL CANCER MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL ANAL CANCER MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: ANAL CANCER MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: ANAL CANCER MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: ANAL CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL ANAL CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 AMGEN INC..: KEY FINANCIALS

FIGURE 15 AMGEN INC.: SEGMENTAL REVENUE

FIGURE 16 AMGEN INC.: REGIONAL REVENUE

FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 18 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 19 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 20 CELGENE CORPORATION: KEY FINANCIALS

FIGURE 21 CELGENE CORPORATION: SEGMENTAL REVENUE

FIGURE 22 CELGENE CORPORATION: REGIONAL REVENUE

FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 26 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 27 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 28 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 29 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 30 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 31 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 32 NOVARTIS AG: KEY FINANCIALS

FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

FIGURE 35 PFIZER INC.: KEY FINANCIALS

FIGURE 36 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 37 PFIZER INC.: REGIONAL REVENUE

FIGURE 38 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 39 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 40 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 41 SANOFI: KEY FINANCIALS

FIGURE 42 SANOFI: SEGMENTAL REVENUE

FIGURE 43 SANOFI: REGIONAL REVENUE

FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 47 HOSPIRA, INC.: KEY FINANCIALS

FIGURE 48 HOSPIRA, INC.: SEGMENTAL REVENUE

FIGURE 49 HOSPIRA, INC.: REGIONAL REVENUE